trending Market Intelligence /marketintelligence/en/news-insights/trending/AldO56qNmgPihlrO2MLfEA2 content esgSubNav
In This List

Maxigen Biotech Q1 loss narrows YOY

Blog

Gold - Geopolitical tensions and inflation remain key drivers

Blog

Lithium and Cobalt - Softer demand weighs on prices

Podcast

Street Talk | Episode 94: Recessionary fears in ’22 overblown, Fed could overtighten

Blog

Insight Weekly: Ukraine war impact on mining; US bank growth slowdown; cloud computing headwinds


Maxigen Biotech Q1 loss narrows YOY

Maxigen Biotech Inc. said its first-quarter normalized net income came to a loss of 9 Taiwan cents per share, compared with a loss of 11 cents per share in the prior-year period.

Normalized net income, which excludes unusual gains or losses on a pre- and after-tax basis, was a loss of NT$6.6 million, compared with a loss of NT$7.8 million in the year-earlier period.

The normalized profit margin rose to negative 10.4% from negative 13.9% in the year-earlier period.

Total revenue rose 13.6% on an annual basis to NT$63.3 million from NT$55.7 million, and total operating expenses grew 6.4% from the prior-year period to NT$72.7 million from NT$68.3 million.

Reported net income came to a loss of NT$11.2 million, or a loss of 16 cents per share, compared to a loss of NT$12.9 million, or a loss of 18 cents per share, in the year-earlier period.

As of May 13, US$1 was equivalent to NT$32.68.